Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 13/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22398651 | 1.00 | MEN1 (0.47) | MEN1KMT2ATLR2CYP2D6CA2 | |
| SCHEMBL22687577 | 0.94 | MEN1 (0.43) | MEN1KMT2ATLR2CYP2D6CA2 | |
| SCHEMBL22398629 | 0.89 | MEN1 (0.41) | MEN1KMT2ATLR2CYP2D6CA2 | |
| SCHEMBL22398630 | 0.89 | MEN1 (0.41) | MEN1KMT2ATLR2CYP2D6CA2 | |
| SCHEMBL15233204 | 0.86 | MEN1 (0.35) | MEN1KMT2ATLR2CYP2D6 | |
| SCHEMBL22398323 | 0.84 | RRM1 (0.46) | MEN1KMT2ADPP7 | |
| SCHEMBL18906348 | 0.84 | MEN1 (0.39) | MEN1KMT2ATLR2CA2 | |
| SCHEMBL18906341 | 0.84 | MEN1 (0.39) | MEN1KMT2ATLR2CA2 | |
| SCHEMBL30951038 | 0.84 | MEN1 (0.41) | MEN1KMT2ATLR2CA2PLK1 | |
| SCHEMBL16368840 | 0.83 | MEN1 (0.46) | MEN1KMT2ACYP2D6CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11465965-B2 | Double-headed protease inhibitor | UBE INDUSTRIES, LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20200347011-A1 | DOUBLE-HEADED PROTEASE INHIBITOR | UBE INDUSTRIES, LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3705471-A1 | DOUBLE-HEADED PROTEASE INHIBITOR | UBE Industries, Ltd. (JP) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347011-A1 | DOUBLE-HEADED PROTEASE INHIBITOR | TMPRSS15, SPINT2, PRSS2 | MEN1 519/4885KMT2A 1556/4885TLR2 3044/4885 |
| US-11465965-B2 | Double-headed protease inhibitor | TMPRSS15, SPINT2, PRSS2 | MEN1 519/4885KMT2A 1556/4885TLR2 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.